Mounting evidence reveal possible forgery of former CEO Bill Chaaban's signature.
The infamous multimillion dollar equity financier of CEN Biotech renegotiates stake for $9.6 million 12% debt bearing note.
Restated financial statements reveal an ugly picture: $8 million working capital deficiency, -67% y/y decline in revenues, and -$15 million in net losses.
In a nutshell, former Creative Edge management left investors with a -$20 million bill from CEN Biotech and nothing to show for it, except a T-Shirt.